EICHOR
● Completed
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Condition: Crohn's Disease · Sponsor: Mesoblast, Inc.
About this study
Protocol 603 is enrolling subjects with moderate-to-severe Crohn's disease who are intolerant to, or have previously failed therapy with, at least one steroid and at least one immunosuppressant and a biologic monoclonal anti-body to tumor necrosis factor alpha. The protocol investigates the safety and efficacy of using PROCHYMAL® adult human stem cells to induce remission. PROCHYMAL is delivered through a vein in the arm four times over two weeks, for approximately an hour each time.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (56)
| University of Southern California University Hospital | Los Angeles, California, United States | — |
| University of California, San Francisco | San Francisco, California, United States | — |
| Western States Clinical Research | Wheat Ridge, Colorado, United States | — |
| Clinical Research of West Florida | Clearwater, Florida, United States | — |
| Borland-Groover Clinic | Jacksonville, Florida, United States | — |
| Shafran Gastroenterology Center | Winter Park, Florida, United States | — |
| Atlanta Gastroenterology Associates | Atlanta, Georgia, United States | — |
| University of Chicago Medical Center | Chicago, Illinois, United States | — |
| Carle Clinic Association | Urbana, Illinois, United States | — |
| Indiana University Medical Center | Indianapolis, Indiana, United States | — |
| Cotton-O'Neil Clinical Research Center | Topeka, Kansas, United States | — |
| University of Kentucky Hospital | Lexington, Kentucky, United States | — |
+ 44 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00482092